CCM
AVIR icon

Coldstream Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

Coldstream Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,188
Closed -$9.53K – 1308
2025
Q1 		$9.53K Buy
+3,188
New +$9.95K ﹤0.01% 2399

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Coldstream Capital Management's AVIR Position: Q2 2025 in Review

Coldstream Capital Management sold out of Atea Pharmaceuticals (AVIR) in Q2 2025, closing a stake of 3,188 shares — an estimated $9.53K sold.

Coldstream Capital Management first reported a position in AVIR in Q1 2025 and held it in 1 quarter. The position peaked at $9.53K in Q1 2025. 106 funds tracked by Wall St. Rank hold AVIR as of Q2 2025.

  • Coldstream Capital Management reported no remaining Atea Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 3,188 Atea Pharmaceuticals shares in Q2 2025, an estimated $9.53K.
  • Coldstream Capital Management first reported a position in Atea Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Atea Pharmaceuticals position peaked at $9.53K in Q1 2025.
  • 106 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.